These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 31177550)

  • 1. Management of bone disease in cystinosis: Statement from an international conference.
    Hohenfellner K; Rauch F; Ariceta G; Awan A; Bacchetta J; Bergmann C; Bechtold S; Cassidy N; Deschenes G; Elenberg E; Gahl WA; Greil O; Harms E; Herzig N; Hoppe B; Koeppl C; Lewis MA; Levtchenko E; Nesterova G; Santos F; Schlingmann KP; Servais A; Soliman NA; Steidle G; Sweeney C; Treikauskas U; Topaloglu R; Tsygin A; Veys K; V Vigier R; Zustin J; Haffner D
    J Inherit Metab Dis; 2019 Sep; 42(5):1019-1029. PubMed ID: 31177550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment of nephropathic cystinosis with cysteamine.
    Kleta R; Gahl WA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.
    Hohenfellner K; Nießl C; Haffner D; Oh J; Okorn C; Palm K; Schlingmann KP; Wygoda S; Gahl WA
    Mol Genet Metab; 2022 Aug; 136(4):282-288. PubMed ID: 35843134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Disease in Nephropathic Cystinosis: Beyond Renal Osteodystrophy.
    Machuca-Gayet I; Quinaux T; Bertholet-Thomas A; Gaillard S; Claramunt-Taberner D; Acquaviva-Bourdain C; Bacchetta J
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32354056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.
    Nesterova G; Williams C; Bernardini I; Gahl WA
    Pediatr Nephrol; 2015 Jun; 30(6):945-51. PubMed ID: 25526929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cystinosis : Diagnosis, cystine-depleting therapy, and transition].
    Kaufeld J; Weber LT; Kurschat C; Canaan-Kuehl S; Brand E; Oh J; Pape L
    Internist (Berl); 2018 Aug; 59(8):861-867. PubMed ID: 29671012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NIH conference. Cystinosis: progress in a prototypic disease.
    Gahl WA; Thoene JG; Schneider JA; O'Regan S; Kaiser-Kupfer MI; Kuwabara T
    Ann Intern Med; 1988 Oct; 109(7):557-69. PubMed ID: 3048161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early oral cysteamine therapy for nephropathic cystinosis.
    Gahl WA
    Eur J Pediatr; 2003 Dec; 162 Suppl 1():S38-41. PubMed ID: 14610675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversies and research agenda in nephropathic cystinosis: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
    Langman CB; Barshop BA; Deschênes G; Emma F; Goodyer P; Lipkin G; Midgley JP; Ottolenghi C; Servais A; Soliman NA; Thoene JG; Levtchenko EN;
    Kidney Int; 2016 Jun; 89(6):1192-203. PubMed ID: 27181776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Negligible urinary cysteamine loss in cystinosis patients with Fanconi syndrome.
    Levtchenko EN; de Graaf-Hess A; Blom HJ; Monnens LA
    Clin Nephrol; 2002 May; 57(5):349-51. PubMed ID: 12036193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephropathic cystinosis in adults: natural history and effects of oral cysteamine therapy.
    Gahl WA; Balog JZ; Kleta R
    Ann Intern Med; 2007 Aug; 147(4):242-50. PubMed ID: 17709758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
    Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
    Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up and treatment of adults with cystinosis in the Netherlands.
    Geelen JM; Monnens LA; Levtchenko EN
    Nephrol Dial Transplant; 2002 Oct; 17(10):1766-70. PubMed ID: 12270982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-term cysteamine treatment in patients with cystinosis.
    Ariceta G; Giordano V; Santos F
    Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenchymal organ cystine depletion with long-term cysteamine therapy.
    Gahl WA; Charnas L; Markello TC; Bernardini I; Ishak KG; Dalakas MC
    Biochem Med Metab Biol; 1992 Dec; 48(3):275-85. PubMed ID: 1476793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cysteamine in renal transplantation: A report of two patients with nephropathic cystinosis and the successful re-initiation of cysteamine therapy during the immediate post-transplant period.
    Berryhill A; Bhamre S; Chaudhuri A; Concepcion W; Grimm PC
    Pediatr Transplant; 2016 Feb; 20(1):141-5. PubMed ID: 26477696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cystinosis in adults: A systemic disease].
    Servais A; Goizet C; Bertholet-Thomas A; Decramer S; Llanas B; Choukroun G; Novo R
    Nephrol Ther; 2015 Jun; 11(3):152-9. PubMed ID: 25769364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between age at initiation of cysteamine treatment, adherence with therapy, and glomerular kidney function in infantile nephropathic cystinosis.
    Nießl C; Boulesteix AL; Oh J; Palm K; Schlingmann P; Wygoda S; Haffner D; Wühl E; Tönshoff B; Buescher A; Billing H; Hoppe B; Zirngibl M; Kettwig M; Moeller K; Acham-Roschitz B; Arbeiter K; Bald M; Benz M; Galiano M; John-Kroegel U; Klaus G; Marx-Berger D; Moser K; Mueller D; Patzer L; Pohl M; Seitz B; Treikauskas U; von Vigier RO; Gahl WA; Hohenfellner K
    Mol Genet Metab; 2022 Aug; 136(4):268-273. PubMed ID: 35835062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body growth, upper arm fat area, and clinical parameters in children with nephropathic cystinosis compared with other pediatric chronic kidney disease entities.
    Kluck R; Müller S; Jagodzinski C; Hohenfellner K; Büscher A; Kemper MJ; Oh J; Billing H; Thumfart J; Weber LT; Acham-Roschitz B; Arbeiter K; Tönshoff B; Hagenberg M; Kanzelmeyer N; Pavičić L; Haffner D; Zivicnjak M
    J Inherit Metab Dis; 2022 Mar; 45(2):192-202. PubMed ID: 34989402
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.